ArticlePediatrics2021
Compassionate Use of Remdesivir in Children With Severe COVID-19.
Article in Pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Remdesivir for the treatment of children hospitalized with COVID-19: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce.Journal of the Pediatric Infectious Diseases Society · 2024Pooled it
- Guidelines for the prevention and management of children and adolescents with COVID-19.European journal of pediatrics · 2022Guideline
- Remdesivir in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Remdesivir safety and clinical outcomes in pediatric COVID-19: a retrospective study.BMC infectious diseases · 2025Article
- Unlocking the potential of remdesivir: innovative approaches to drug delivery.Drug delivery and translational research · 2025Review
- Targeted peptide modification of mesenchymal stem cells enhances their therapeutic efficacy in the treatment of idiopathic pulmonary fibrosis.Frontiers in cell and developmental biology · 2025Article
- Safety of remdesivir in the treatment of acute SARS-CoV-2 infection in pediatric patients.BMC infectious diseases · 2024Observational
- Views and insights into the remdesivir study for the treatment of severe pediatric COVID-19 cases.Health science reports · 2024Article
- Treatment with Remdesivir of Children with SARS-CoV-2 Infection: Experience from a Clinical Hospital in Romania.Life (Basel, Switzerland) · 2024Article
- Use of Remdesivir in children with COVID-19: report of an Italian multicenter study.Italian journal of pediatrics · 2024Article
- Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study.Molecular and cellular pediatrics · 2024Article
- Evaluation of the safety profile and therapeutic efficacy of remdesivir in children with SARS-CoV-2 infection - a single-center, retrospective, cohort study.European journal of pediatrics · 2024Article
- COVID-19 among infants: key clinical features and remaining controversies.Clinical and experimental pediatrics · 2024Article
- The Therapy of SARS-CoV-2 Infection in Children.Journal of clinical medicine · 2023Review
- Remdesivir therapy for severe pediatric COVID-19 in Singapore: A single-center retrospective observational cohort study.Health science reports · 2023Article
- Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.Orphanet journal of rare diseases · 2023Article
- Safety and Tolerability of Remdesivir in Infants and Children with COVID-19.Indian journal of pediatrics · 2023Article
- Remdesivir: A Review in COVID-19.Drugs · 2023Review
- Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRemdesivir shortens time to recovery in adults with severe coronavirus disease 2019 (COVID-19), but its efficacy and safety in children are unknown. We describe outcomes in children with severe COVID-19 treated with remdesivir.
methodsSeventy-seven hospitalized patients <18 years old with confirmed severe acute respiratory syndrome coronavirus 2 infection received remdesivir through a compassionate-use program between March 21 and April 22, 2020. The intended remdesivir treatment course was 10 days (200 mg on day 1 and 100 mg daily subsequently for children ≥40 kg and 5 mg/kg on day 1 and 2.5 mg/kg daily subsequently for children <40 kg, given intravenously). Clinical data through 28 days of follow-up were collected.
resultsMedian age was 14 years (interquartile range 7-16, range <2 months to 17 years). Seventy-nine percent of patients had ≥1 comorbid condition. At baseline, 90% of children required supplemental oxygen and 51% required invasive ventilation. By day 28 of follow-up, 88% of patients had a decreased oxygen-support requirement, 83% recovered, and 73% were discharged. Among children requiring invasive ventilation at baseline, 90% were extubated, 80% recovered, and 67% were discharged. There were 4 deaths, of which 3 were attributed to COVID-19. Remdesivir was well tolerated, with a low incidence of serious adverse events (16%). Most adverse events were related to COVID-19 or comorbid conditions. Laboratory abnormalities, including elevations in transaminase levels, were common; 61% were grades 1 or 2.
conclusionsAmong 77 children treated with remdesivir for severe COVID-19, most recovered and the rate of serious adverse events was low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.